Rimonabant for Cognitive Impairment in People With Post-COVID-19 Syndrome
Key facts
- Who runs it
- Sinfatin S.L
- Where
- Spain4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 2
- People taking part
- 80 people, planned
- Started
- 6 Nov 2026
- Expected to end
- Mar 2028
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Rimonabant
- Placebo
- Record updated
- 12 November 2026
Who can take part
- Age
- 18 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (22)Hide the full registry criteria
Who can take part
- Age between 18 and 75 years (both inclusive)
- Have had COVID-19 at least 3 months before joining the study
- Have been diagnosed with active PCS (Long COVID)
- Have ongoing problems with memory or concentration due to long-COVID syndrome
- Show signs of cognitive impairment in study assessments
- Be willing to complete study assessments
- Be able to understand and speak Spanish
- Provide written consent to participate
Who cannot take part
- Use substances or medications that may affect memory or concentration
- Have an active or recent COVID-19 infection
- Have severe mental health conditions, a pprevious suicide attempt
- Have neurological conditions that may affect memory or concentration
- Have other medical conditions that could explain their symptoms
- Have severe lung, heart, liver, kidney, or bone disease
- Have a known allergy to rimonabant
- Have a high risk of suicide
- Have a body mass index (BMI) greater than 40 kg/m²
- Are unable to walk or attend study visits
- Are taking medicines that may interact with the study treatment
- Have taken part in another clinical trial within the last month
- Are pregnant or breastfeeding
- Are able to become pregnant or father a child and are not using effective contraception
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Post-COVID-19 syndrome
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The main goal of the study is to assess the effect of rimonabant in cognitive performance in patients with Post-COVID-19 Syndrome, also known as long COVID.
Read full original descriptionShow less
The study will include 80 adults aged 18 to 75 years that will receive either rimonabant (5 mg) or placebo (a look-alike tablet that contains no drug) once daily for 90 days. Neither the participants nor the investigators will know which treatment is being given.
The study will also help to learn about the safety of rimonabant.
The 2 groups in the trial
- Rimonabant 5 mgTreatment being tested
Participants receive rimonabant 5 mg orally once daily for 90 days.
Treatment: Rimonabant
- PlaceboPlacebo, for comparison
Participants receive matching placebo orally once daily for 90 days.
Next steps
For your doctor
Doctor ask sheet
A PDF for your doctor: what this trial tests, who can take part, and 2 eligibility questions with room for answers and notes.
PDF, US Letter, 1 to 2 pages. A4 size
For the study team
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Effects of a CB1 Receptor Antagonist/Inverse Agonist (Rimonabant) on the Improvement of Cognitive Impairment in Patients With Post-COVID-19 Syndrome (RIMOCOVID-1)
- Criteria questions
- Built from NCT07930637, who can take part
- Record updated
- 12 November 2026